MedTrace Logo

Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia

NCT01356472 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-05-19

No results posted yet for this study

Summary

As previous studies showed that the synergy between linezolid and carbapenem in vitro and in vivo (animal studies), our study is aim to investigate the activity of linezolid, alone and in combination with carbapenem against methicillin-resistant Staphylococcus aureus (MRSA) in ventilator-associated pneumonia (VAP) patients.

Conditions

  • Methicillin-resistant Staphylococcus Aureus
  • Pneumonia, Ventilator-Associated

Interventions

DRUG

Imipenem/cilastatin

the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Er-Zhen Chen, M.D. & Ph.D. · Emergency intensive care unit, Ruijin Hospital

  • Hong-Ping Qu, M.D. · Respiratory intensive care unit, Ruijin Hospital

  • Yu-Xing Ni, M.D. & Ph.D. · Microbiology laboratory, Ruijin Hospital

  • Zhi-Tao Yang, M.D. · Emergency Department, Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01356472 on ClinicalTrials.gov